Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Published:2021-07 Issue:7 Volume:6 Page:559-568
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Qin Shukui,Li Qiu,Gu Shanzhi,Chen Xiaoming,Lin Lizhu,Wang Zishu,Xu Aibing,Chen Xi,Zhou Cuncai,Ren Zhenggang,Yang Lin,Xu Li,Bai Yuxian,Chen Lei,Li Jun,Pan Hongming,Cao Bangwei,Fang Weijia,Wu Wei,Wang Ge,Cheng Ying,Yu Zhuang,Zhu Xu,Jiang Da,Lu Yinying,Wang Huaming,Xu Jianming,Bai Li,Liu Yunpeng,Lin Hailan,Wu Changping,Zhang Yang,Yan Ping,Jin Chunlei,Zou Jianjun

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference35 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis;El-Serag;Gastroenterology,2007

3. Treatment modalities for hepatocellular carcinoma;Hung;Curr Cancer Drug Targets,2005

4. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis;Tabrizian;Ann Surg,2015

5. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2);Allemani;Lancet,2015

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapies for Hepatocellular Carcinoma Treatment;Liver Cancer - Multidisciplinary Approach;2024-09-11

2. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer;Cancer Immunology, Immunotherapy;2024-09-05

3. Thymic epithelial tumor medical treatment: A narrative review;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. A pH-Responsive Drug-Delivery System Based on Apatinib-Loaded Metal-Organic Frameworks for Ferroptosis-Targeted Synergistic Anti-Tumor Therapy;International Journal of Nanomedicine;2024-09

5. Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): a single-arm, phase II study;European Journal of Cancer;2024-09